Format

Send to

Choose Destination
Clin Nucl Med. 2016 Mar;41(3):204-6. doi: 10.1097/RLU.0000000000000973.

Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.

Author information

1
From the Departments of *Diagnostic Imaging and †Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.

Abstract

A 22-year-old woman with rapidly progressing metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation, who recurred after neoadjuvant chemotherapy, was found to be MIBG avid. She was treated with 2 I-MIBG treatments and concurrent sunitinib, achieving a complete response. She was in full remission for 9 months before developing bone metastases.

PMID:
26359568
DOI:
10.1097/RLU.0000000000000973
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center